Author:
Gaudy-Marqueste C.,Ciccolini J.
Reference9 articles.
1. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs;Serdjebi;Expert Opin Drug MetabToxicol,2015
2. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective;Ciccolini;Cancer Chemotherapy and Pharmacology,2016
3. High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications;Donnette;AnnOncol,2021
4. Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA;Gemble;PloSGenet,2015
5. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer;Pantelidou;Cancer Discov,2019